Riza M. Daza

Riza M. Daza

Auto-generated profile, based on publicly available information

Riza M. Daza

University of Washington

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DCDiego Calderon
Diego Calderon
AEAndria Ellis
Andria Ellis
RDRiza M. Daza
Riza M. Daza
BMBeth Martin
Beth Martin
JTJacob M. Tome
Jacob M. Tome
JSJay Shendure
Jay Shendure
Gene regulation occurs through trans -acting factors ( e.g. transcription factors) acting on cis -regulatory elements ( e.g. enhancers). Massively parallel reporter assays (MPRAs) functionally survey large numbers of cis -regulatory elements for regulatory potential, but do not identify the trans -acting factors that mediate any observed effects. Here we describe trans MPRA — a reporter assay that efficiently combines multiplex CRISPR-mediated perturbation and MPRAs to identify trans- acting factors that modulate the regulatory activity of specific enhancers.

5 April 2018 in bioRxiv
Verified
Preprint
Open access
PDF file
GFGregory M. Findlay
Gregory M. Findlay
RDRiza M. Daza
Riza M. Daza
BMBeth Martin
Beth Martin
MZMelissa D. Zhang
Melissa D. Zhang
ALAnh P. Leith
Anh P. Leith
JSJay Shendure
Jay Shendure
Variants of uncertain significance (VUS) fundamentally limit the utility of genetic information in a clinical setting. The challenge of VUS is epitomized by BRCA1 , a tumor suppressor gene integral to DNA repair and genomic stability. Germline BRCA1 loss-of-function (LOF) variants predispose women to early-onset breast and ovarian cancers. Although BRCA1 has been sequenced in millions of women, the risk associated with most newly observed variants cannot be definitively assigned. Data sharing attenuates this problem but it is unlikely to solve it, as most newly observed variants are exceedingly rare. In lieu of genetic evidence, experimental approaches can be used to functionally characterize VUS. However, to date, functional studies of BRCA1 VUS have been conducted in a post hoc , piecemeal fashion. Here we employ saturation genome editing to assay 96.5% of all possible single nucleotide variants (SNVs) in 13 exons that encode functionally critical domains of BRCA1. Our assay measures cellular fitness in a haploid human cell line whose survival is dependent on intact BRCA1 function. The resulting function scores for nearly 4,000 SNVs are bimodally distributed and almost perfectly concordant with established assessments of pathogenicity. Sequence-function maps enhanced by parallel measurements of variant effects on mRNA levels reveal mechanisms by which loss-of-function SNVs arise. Hundreds of missense SNVs critical for protein function are identified, as well as dozens of exonic and intronic SNVs that compromise BRCA1 function by disrupting splicing or transcript stability. We predict that these function scores will be directly useful for the clinical interpretation of cancer risk based on BRCA1 sequencing. Furthermore, we propose that this paradigm can be extended to overcome the challenge of VUS in other genes in which genetic variation is clinically actionable.